Cas9 Stable Cell Line - PANC-1

PANC-1 is a mature human pancreatic cancer cell line originally derived from pancreatic ductal epithelial cells of pancreatic cancer patients. It is widely used as an in vitro model for studying the biology of pancreatic ductal adenocarcinoma. These cells typically exhibit epithelial-like morphology, adherently grow under standard culture conditions, and are known for their robust proliferative capacity, genomic instability, and tumor-associated molecular signatures. Due to the highly aggressive nature of pancreatic cancer and its frequent resistance to conventional therapies, PANC-1 has become an important model for studying cancer cell signaling, epithelial-mesenchymal transition, invasion, migration, drug resistance, and metabolic adaptation. The Cas9 stable cell line – PANC-1 refers to a genetically engineered PANC-1 cell line that stably expresses the CRISPR-associated nuclease Cas9. By integrating the Cas9 expression cassette into the PANC-1 genome and screening for stable clones or mixed cell populations, this cell product provides a ready-to-use platform for CRISPR-based genome editing.

The Cas9 stable cell line – PANC-1 can be applied to a wide range of research fields, particularly cancer biology, gene function analysis, target discovery, and therapeutic drug development. One of the main applications of this product is single-gene knockout research, where researchers can use this technology to deliver sgRNAs targeting oncogenes, tumor suppressor genes, signaling molecules, transcription factors, metabolic enzymes, or drug resistance-related genes to assess the roles of these genes in PANC-1 cell growth, survival, migration, invasion, apoptosis, and treatment response. This product is also suitable for CRISPR-based co-screening, including genome-wide or pathway-specific loss-of-function screening, to identify genes crucial for pancreatic cancer cell survival or those regulating sensitivity to chemotherapy, targeted therapy, immunomodulatory compounds, or metabolic stress. Since PANC-1 cells are often used to mimic the phenotype of invasive pancreatic cancer, Cas9 stable derivatives can help researchers explore the potential mechanisms of interactions related to epithelial-mesenchymal transition, KRAS-related signaling pathways, DNA damage responses, autophagy, hypoxia adaptation, and the tumor microenvironment.